Surgery Partners, Inc. Announces Second Quarter 2026 Results Reaffirms Full Year 2026 Guidance

Surgery Partners reported Q2 revenue of $848.9M (+2.7% YoY) and same-facility revenue +5.0% YoY, but Adjusted EBITDA slipped to $125.2M (from $129.0M). GAAP net loss attributable to the company was $15.0M versus a $2.5M loss a year ago, alongside weaker operating cash flow ($59.3M vs. $81.3M). The company reaffirmed FY2026 guidance of $3.35B–$3.45B revenue and at least $530M Adjusted EBITDA, excluding the pending Idaho Falls divestiture (subject to approvals), which it says should strengthen cash conversion and deleveraging.

Analysis

This is a margin-compression print disguised as a growth update. Revenue-per-case is doing the work while case growth is basically flat, so the earnings bridge is highly dependent on operating leverage that is currently leaking into labor, supplies, and integration costs. With leverage still elevated, small EBITDA disappointments matter more than the headline revenue stability; the market should care more about cash conversion than about a reaffirmed range.

The divestiture narrative is directionally positive for the balance sheet, but it is not automatically accretive to equity value if management uses the clean-up phase to de-risk rather than reaccelerate higher-return ASC expansion. Second-order, a more cautious SGRY likely means less competitive pressure for better-capitalized outpatient platforms like THC’s USPI franchise and HCA’s ambulatory footprint, because physician partners usually prefer counterparties with lower execution and financing risk.

Near term, the catalyst path is closing risk on the asset sale and management commentary on 2027 capital allocation; over 6-18 months the question is whether same-facility cases can inflect above low-single digits without another round of restructuring spend. Consensus may be underpricing the duration of the margin reset: reaffirmed guidance can coexist with weaker incremental economics if SG&A, labor, and transaction costs stay sticky. The thesis is falsified if Q3-Q4 margin expands back above ~15% and case growth meaningfully re-accelerates, because then deleveraging becomes a true EPS tailwind rather than a defensive maneuver.

Key Decisions for Investors

• Relative value: long THC / short SGRY for 1-3 months. Thesis is that USPI’s better balance sheet and broader payer/physician relationships should outperform if SGRY stays in portfolio-optimization mode. Falsify if SGRY posts margin reacceleration and higher case growth in the next quarter.
• Avoid initiating outright longs in SGRY on the reaffirmed guide. Wait for a post-call bounce to fade unless management provides explicit evidence that EBITDA margin can recover above 15% without incremental transaction costs.
• Watch for a closing announcement on the Idaho Falls divestiture as a de-risking catalyst, but treat it as a leverage event rather than an earnings event. If net debt/EBITDA drops below 4.0x without guidance uplift, that is likely only a multiple-supportive move, not an alpha driver.
• If options liquidity is acceptable, use SGRY downside puts or a put spread into the next quarter only on a rally, not immediately after the print. Risk/reward improves if the market starts extrapolating the asset sale into a cleaner margin story that the operating data does not yet support.